
Mallinckrodt Investor Relations Material
Latest events

Q1 2025
Mallinckrodt
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mallinckrodt plc
Access all reports
Mallinckrodt plc is a specialty pharmaceutical company that focuses on developing, manufacturing, and commercializing treatments for autoimmune and rare diseases, as well as therapies for pain management and critical care. The company’s portfolio includes a range of branded and generic pharmaceuticals, with a strong emphasis on specialty therapies for conditions such as neurology, nephrology, rheumatology, and pulmonology. Mallinckrodt also offers imaging agents used in diagnostic procedures. Its products are primarily distributed to hospitals, physicians, and healthcare providers. The company is headquartered in Dublin, Ireland, and its shares are listed on the New York Stock Exchange.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
MNK
Country
🇺🇸 United States